LSE - Delayed Quote EUR

Euroapi S.A. (0EAP.L)

15.86

+0.25

+(1.57%)

As of July 22 at 8:22:54 AM GMT+1. Market Open.

Combined General Meeting of May 21, 2025

Press Release - Approval of all resolutions submitted by the Board of Directors, including the unconsolidated and consolidated financial statements for the year 2024 - Paris – May 21, 2025 – The Combined General Shareholders’ Meeting of EUROAPI was held on May 21, 2025 in Paris, under the chairmanship of Emmanuel Blin. All resolutions put forth to a vote were adopted by the shareholders. The General Meeting approved the unconsolidated and consolidated financial statements for the year 2024, all

GlobeNewswire 6 days ago

EAPIF
Combined General Meeting of May 21, 2025 - Availability of preparatory documents

Press Release Paris – April 29, 2025 – EUROAPI’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 21, 2025 at 10:30 a.m. (CET) at 15 bis, rue Traversière 75012 Paris. The notice of meeting was published at the French official legal announcement publication (BALO) on Wednesday April 16, 2025 and the convening notice (avis de convocation) was published in the Actu-juridique.fr, a French journal of legal notice, on April 28, 2025. The documents and informa

GlobeNewswire 28 days ago

EAPIF
Availability of the 2024 Universal Registration Document, including the Annual Financial Report

Press Release Paris – April 1, 2025 – EUROAPI announces the publication of its 2024 Universal Registration Document in ESEF format, filed with the French Autorité des marchés financiers (AMF) on April 1, 2025. The 2024 Universal Registration Document contains in particular: The annual financial report, including the management report that encompasses namely the Corporate Governance report, the sustainability statement and the company and consolidated statements;The statutory auditors’ reports, i

GlobeNewswire last month

EAPIF
Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline

Press Release Paris, 3rd March, 2025 Full-year 2024 results1: Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only partly offset by encouraging commercial momentumCore EBITDA at €50.4m, with margin down 370bps year-on-year to 5.5%, due notably to unfavorable fixed cost impact€(43.6) million EBITDA, including €87.1 mill

GlobeNewswire 2 months ago

EAPIF
EUROAPI welcomes the French Minister for Health and Access to Healthcare Yannick Neuder and the French Minister for Industry and Energy Marc Ferracci to its Puy-de-Dôme site

Press Release A tour of Vertolaye manufacturing and storage facilities highlighted EUROAPI’s long-term commitment to health sovereignty Paris and Vertolaye - January 6, 2025 – The French Minister for Health and Access to Healthcare Yannick Neuder and the French Minister for Industry and Energy Marc Ferracci visited today EUROAPI’s industrial site in Vertolaye (Puy-de-Dôme), accompanied by members of parliament and local elected representatives. The Vertolaye plant specializes in corticosteroids,

GlobeNewswire 4 months ago

EAPIF
EUROAPI moves into a new chapter with new Governance and Leadership

Press Release Emmanuel Blin appointed Independent Chair of the Board of DirectorsDavid Seignolle appointed Chief Executive OfficerFull-year 2024 guidance maintained Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company’s Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the reco

GlobeNewswire 5 months ago

EAPIF
Olivier Falut appointed EUROAPI’s Chief Financial Officer

Press Release Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. “I am delighted to welcome Olivier, a seasoned Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in implementing our FOCUS-27 tra

GlobeNewswire 7 months ago

EAPIF
EUROAPI closes the financing of its FOCUS-27 plan

Press Release Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing the financing of its FOCUS-27 strategic plan. About EUROAPIEUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in

GlobeNewswire 7 months ago

EAPIF
EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution

Press Release €451M Revolving Credit Facility refinanced with a maturity extended to February 2029Issuance of a €200M Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi€54M product capacity reservation for five products and further amendments to the global Manufacturing and Supply Agreement (MSA) agreed with Sanofi “The completion of the financing is an instrumental step in the execution of EUROAPI’s strategic roadmap” said Ludwig de Mot, Chief Executive Officer. “Combined with furth

GlobeNewswire 7 months ago

EAPIF
EUROAPI - Availability of 2024 Half-Year Financial Report

Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. This report includes notably the 2024 half-year management report, the consolidated financial statements on 30 June 2024, and the Statutory Auditors’ review report on the half-yearly financi

GlobeNewswire 9 months ago

EAPIF
H1 2024 Results - Focus-27 strategic plan on track with timely execution of the operational roadmap

Press ReleaseParis, 30th July 2024 Net Sales down 9.6% year-on-year – Core EBITDA margin at 10.6%Accelerated commercial momentum with clients other than Sanofi, with Net Sales up 2.9%, excluding the Brindisi site, where production was temporarily suspendedEnhanced effectiveness across the entire organization, with sizeable improvements in industrial efficiencies€10 million Free Cash Flow before financing, driven by strengthened financial disciplineFY 2024 guidance confirmed " Our H1 actions set

GlobeNewswire 9 months ago

EAPIF
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1

Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments and production during Q3 202

GlobeNewswire 10 months ago

EAPIF
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

Press Release EUROAPI and Priothera, a biotechnology company specializing in the treatment of hematological malignancies and the improvement of CAR-T cell therapies, have signed a 5-year CDMO agreementEUROAPI will develop and industrialize the manufacturing process of innovative complex molecule for blood cancers Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules

GlobeNewswire 11 months ago

EAPIF
Market update : FOCUS-27 transformation project financing

Press release Paris – June 6, 2024 – EUROAPI informs that it has decided to be assisted by a mandataire ad hoc in its discussions initiated in February 2024 regarding the mid-term and long-term financing of its FOCUS-27 strategic transformation project. The mandat ad hoc is an amicable procedure launched at the company's initiative and conducted within a confidential and legally secured framework. EUROAPI has appointed such an independent third party proactively to accelerate the outcome of the

GlobeNewswire 11 months ago

EAPIF
EUROAPI reaches major Health IPCEI milestone with official notification from European Commission

Press Release Paris – June 6, 2024 – EUROAPI has received official notification from the European Commission that the Company has been selected as one of the 13 companies eligible to share up to EUR 1 billion in total public funding under the Important Project of Common European Interest (IPCEI) dedicated to the pharmaceutical sector, “IPCEI Med4Cure”. This IPCEI had been jointly notified by six Member States of the European Union, i.e. France, Belgium, Hungary, Italy, Slovakia and Spain as a me

GlobeNewswire 11 months ago

EAPIF

Performance Overview

Return	0EAP.L	MSCI WORLD (^990100-USD-STRD)
YTD	+465.15%	+4.28%
1-Year	+337.22%	+11.60%
3-Year	+7.66%	+37.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Euroapi S.A. (0EAP.L)

Combined General Meeting of May 21, 2025

Combined General Meeting of May 21, 2025 - Availability of preparatory documents

Availability of the 2024 Universal Registration Document, including the Annual Financial Report

Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline

EUROAPI welcomes the French Minister for Health and Access to Healthcare Yannick Neuder and the French Minister for Industry and Energy Marc Ferracci to its Puy-de-Dôme site

EUROAPI moves into a new chapter with new Governance and Leadership

Olivier Falut appointed EUROAPI’s Chief Financial Officer

EUROAPI closes the financing of its FOCUS-27 plan

EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution

EUROAPI - Availability of 2024 Half-Year Financial Report

H1 2024 Results - Focus-27 strategic plan on track with timely execution of the operational roadmap

EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1

EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

Market update : FOCUS-27 transformation project financing

EUROAPI reaches major Health IPCEI milestone with official notification from European Commission

Performance Overview